Displaying drugs 13501 - 13525 of 15155 in total
MRG-003
MRG-003 is a recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated to monomethyl auristatin E.
Investigational
A166
A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable valine citrulline linker.
Investigational
AAV-AQP1
Investigational
Ozuriftamab vedotin
Investigational
Deoxynucleogene ancparvovec
Investigational
AML-2-23
Investigational
CypCaps
Investigational
DNP-Modified autologous tumor vaccine
Investigational
Myb34.5
Investigational
Albumin-stabilized nanoparticle (130 nm)
Investigational
Boserolimab
Investigational
CD8+ enriched young tumor infiltrating lymphocytes
Investigational
TASO-001
TASO-001 is a transforming growth factor (TGF)-beta 2 specific antisense oligodeoxynucleotide.
Investigational
CD-16 NK-92 cells
Investigational
LP-2307
LP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.
Investigational
APL-502
APL 502 is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1 (PD-L1).
Investigational
Anselamimab
Investigational
Autogene cevumeran
Autogene cevumeran is an mRNA-based cancer vaccine targeting an unspecified amount of tumour-associated antigens. It is being investigated for cancers.
Investigational
VB10.16
VB10.16 is a novel therapeutic antigen-presenting cell-targeting DNA vaccine developed to treat HPV16-positive cancers. It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting cells (APCs).
Investigational
Matched Description: … encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and …
Casdozokitug
Investigational
Batiraxcept
Investigational
ETBX-051
Investigational
RO7296682
RO7296682 is a monoclonal antibody against CD25 (IL-2R alpha) expressed on tumour-infiltrating regulatory T (Treg) cells. RO7296682 is under investigation in clinical trial NCT04642365 (A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.).
Investigational
Matched Description: … RO7296682 is under investigation in clinical trial NCT04642365 (A Study to Evaluate the Safety and Tolerability …
GCS-100
Investigational
Displaying drugs 13501 - 13525 of 15155 in total